Scancell shares jump on trial expansion for Modi-1 vaccine

(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the ...

Alliance News 31 July, 2023 | 9:23AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients.

Shares in the Nottingham, England-based cancer immunotherapies developer were up 25% at 11.53 pence each in London on Monday morning.

Scancell said the safety review committee has approved the addition of two new cohorts of 21 patients each.

This move follows the successful completion of cohort four of the trial, which showed that patients with renal, head and neck cancer who received at least two doses of Modi-1 combined with CPI tolerated the treatment well, with no safety concerns.

The trial will not include patients suffering from breast cancer.

In addition, the company said recruitment into the neoadjuvant arm of the Modi-1 trial in combination with CPI was also approved. The study will recruit 30 patients who will receive either two doses of Modi-1 three weeks apart or two doses of Modi-1 plus one dose of CPI.

Modi-1 is a vaccine which targets anti-tumour activity.

Chief Executive Officer Lindy Durrant said: "This is an important milestone for the company as we now have approval to treat patients with Modi-1 monotherapy or in combination with a CPI in four different tumour types either pre- or post-tumour resection. The information extracted from this study will be invaluable in defining the patient population that will benefit the most from our cancer vaccine, Modi-1."

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Scancell Holdings PLC 9.88 GBX 1.80 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures